ReviewGynecology and pelvic medicine2024
Minimally invasive cytoreduction for advanced-stage ovarian cancer-a narrative review.
Review in Gynecology and pelvic medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Ovarian cancer is associated with high morbidity and mortality. Traditional open surgical approaches for ovarian cancer often entail extensive radical surgery leading to prolonged recovery times. Minimally invasive surgery (MIS) has become a promising alternative for gynecological malignancies, offering potential benefits such as reduced perioperative morbidity, faster recovery, and comparable oncologic outcomes. Despite increasing adoption, the role of MIS in the management of ovarian cancer requires further elucidation. This narrative review aims to summarize the current evidence on the role of MIS in the treatment of advanced-stage ovarian cancer. Specifically, it seeks to evaluate the feasibility, and oncologic outcomes associated with MIS approaches, including laparoscopic and robotic-assisted techniques. Methods: A narrative review was performed, including all pertinent publication pertaining to MIS cytoreduction for advanced stage ovarian cancer. We did not follow a systematic review pathway and included all study designs. Key Content and Findings: MIS cytoreduction for advanced stage ovarian cancer is feasible and gaining popularity, mainly in the context of increased utilization of neoadjuvant chemotherapy. No level I evidence is available regarding the oncological safety of this approach, but notwithstanding a significant risk of selection bias, retrospective data suggest that the progression-free survival and overall survival might not be jeopardised. Conclusions: In an era where lifespan, but also health span are gaining importance, tailored cytoreductive surgery using MIS could be of value for selected patients, aiming to minimize morbidity and maximize quality of life in advanced stage ovarian cancer without compromising oncologic outcomes. Based on the available published literature, MIS cytoreduction, mainly since the introduction of neo-adjuvant chemotherapy and the robotic platform, is a promising option for patients and warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.